SNS-032

SNS-032

CAT N°: 17904
Price:

From 66.00 56.10

Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. SNS-032 is an ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively.{29268} It is selective for these kinases and displays no additional activity against a panel of 190 kinases (IC50s = >1,000 nM).{29268} SNS-032 can block the cell cycle, inhibit transcription, and induce apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 µM.{29269} This compound has been shown to induce apoptosis by inhibiting the transcription of the anti-apoptotic proteins, Mcl-1 and XIAP.{29270}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide
  • Correlated keywords
    • 936487-64-8 345627-92-1 345627-90-9 cancer apoptosis inhibitor Cdk9 Cdk7 Cdk2 Cdk-9 Cdk-7 Cdk-2 cyclin-dependent kinase SNS032 BMS387032 inhibit biochemical cell cycle intracellular signaling protein selective ATP
  • Product Overview:
    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. SNS-032 is an ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively.{29268} It is selective for these kinases and displays no additional activity against a panel of 190 kinases (IC50s = >1,000 nM).{29268} SNS-032 can block the cell cycle, inhibit transcription, and induce apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 µM.{29269} This compound has been shown to induce apoptosis by inhibiting the transcription of the anti-apoptotic proteins, Mcl-1 and XIAP.{29270}

We also advise you